Carboplatin treatment of antiestrogen-resistant breast cancer cells

International Journal of Oncology

Volumn 41, Issue 5, 2012, Pages 1863-1870

  Larsen, Mathilde S ^a,b   Yde, Christina W ^a   Christensen, Ib J ^c   Lykkesfeldt, Anne E ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c FINSEN LABORATORY   (Denmark)

Author keywords

Antiestrogen resistance; Breast cancer; Carboplatin; MCF 7

Indexed keywords

ANTIESTROGEN; CARBOPLATIN; CISPLATIN; FULVESTRANT; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; TAMOXIFEN;

ANTIESTROGEN RESISTANT BREAST CANCER CELL LINE; ARTICLE; BREAST CANCER; CANCER CELL; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TAMOXIFEN RESISTANT BREAST CANCER; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BREAST NEOPLASMS; CARBOPLATIN; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION; HUMANS; MCF-7 CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; TAMOXIFEN;

EID: 84867804873     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1623     Document Type: Article

References (31)

1. Ali S and Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-112, 2002. (Pubitemid 37328797)
2. Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, Sutcliffe FA and Walton P: Pharmacokinetics, pharmacological and anti-tumour effects of the specific antioestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 74: 300-308, 1996. (Pubitemid 26254149)
3. Go RS and Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17: 409-422, 1999. (Pubitemid 29022420)
4. Perez EA: Carboplatin in combination therapy for metastatic breast cancer. Oncologist 9: 518-527, 2004.
5. Carrick S, Ghersi D, Wilcken N and Simes J: Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 3: CD003374, 2004.
6. Martin M: Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2: 190-208, 2001.
7. Decatris MP, Sundar S and O'Byrne KJ: Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 30: 53-81, 2004. (Pubitemid 38240088)
8. Colbern GT, Hiller AJ, Musterer RS, Working PK and Henderson IC: Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model. J Inorg Biochem 77: 117-120, 1999. (Pubitemid 30089091)
9. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F and Slamon D: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251, 1999. (Pubitemid 29186925)
10. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA and Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671, 1998. (Pubitemid 28363029)
11. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A and Crown J; Breast Cancer International Research Group: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365: 1273-1283, 2011.
12. Yde CW, Gyrd-Hansen M, Lykkesfeldt AE, Issinger OG and Stenvang J: Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther 6: 1869-1876, 2007. (Pubitemid 46954064)
13. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003. (Pubitemid 37487159)
14. Schorr K, Li M, Krajewski S, Reed JC and Furth PA: Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J Mammary Gland Biol Neoplasia 4: 153-164, 1999.
15. Yde CW and Issinger OG: Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1. Int J Oncol 29: 1397-1404, 2006.
16. Christensen GL, Jepsen JS, Fog CK, Christensen IJ and Lykkesfeldt AE: Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment. Breast Cancer Res Treat 85: 53-63, 2004. (Pubitemid 38437982)
17. Larsen SS, Heiberg I and Lykkesfeldt AE: Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells. Br J Cancer 84: 686-690, 2001. (Pubitemid 32239004)
18. R-1. Cancer Res 54: 1587-1595, 1994.
19. Lykkesfeldt AE, Larsen SS and Briand P: Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 61: 529-534, 1995.
20. Madsen MW, Reiter BE, Larsen SS, Briand P and Lykkesfeldt AE: Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res 57: 585-589, 1997. (Pubitemid 27085636)
21. Sekine I, Shimizu C, Nishio K, Saijo N and Tamura T: A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. Int J Clin Oncol 14: 112-119, 2009.
22. Lykkesfeldt AE and Sorensen EK: Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol 31: 131-138, 1992.
23. Lykkesfeldt AE and Briand P: Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. Br J Cancer 53: 29-35, 1986. (Pubitemid 16156083)
24. Lundholt BK, Briand P and Lykkesfeldt AE: Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat 67: 199-214, 2001. (Pubitemid 32803526)
25. Frogne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ II, de Cremoux P, Stenvang P and Lykkesfeldt AE: Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 114: 263-275, 2009.
26. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S and Reed JC: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55: 4471-4478, 1995.
27. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P and Dogliotti L: p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6: 2751-2758, 2000. (Pubitemid 30482114)
28. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994. (Pubitemid 24163411)
29. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F and Veronesi U: The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994. (Pubitemid 24111005)
30. Benbrook DM, Masamha CP: The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis. Curr Cancer Drug Targets 11: 586-599, 2011.
31. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL and Lykkesfeldt AE: Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 12: 599-614, 2005. (Pubitemid 41482995)